Therapeutics News and Research

RSS

Novel antidepressant targets brain receptors responsible for learning and memory

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

7 Dec 2012

Ultrasound applied to fingertips can stimulate sensory pathways leading to the brain

A century after the world's first ultrasonic detection device - invented in response to the sinking of the Titanic -Virginia Tech Carilion Research Institute scientists have provided the first neurophysiological evidence for something that researchers have long suspected: ultrasound applied to the periphery, such as the fingertips, can stimulate different sensory pathways leading to the brain.

7 Dec 2012

NCI-funded study to identify metabolic vulnerabilities of particularly aggressive cancers

Eileen White, PhD, associate director for basic science at The Cancer Institute of New Jersey and professor of molecular biology and biochemistry at Rutgers, The State University of New Jersey, and colleagues from Princeton University have been awarded a new five-year, $2.4 million dollar research grant from the National Cancer Institute.

7 Dec 2012

Genomic sequencing reveals therapeutic drug targets for metastatic triple-negative breast cancer

Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.

7 Dec 2012

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Whole genome sequencing has revealed previously unreported mutations in metastatic triple-negative breast cancer (TNBC), according to a study published by the journal Molecular Cancer Therapeutics.

6 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

Study questions value of coated, low-dose aspirin therapy

Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets - blood cells that clump together in the first stages of forming harmful clots - up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.

6 Dec 2012

Moderna Therapeutics closes $40M in financing

Moderna Therapeutics announced today that it has closed more than $40 million in financing to date, led by Flagship Ventures and private investors, which will be used to advance multiple programs toward clinical stage development.

6 Dec 2012

Inserm prizes for medical research to be awarded on Dec. 3

The 2012 Inserm prizes for medical research will be awarded at a ceremony at the Coll-ge de France on Monday 3 December 2012. This year, the grand prize will be awarded to Philippe Sansonetti in the presence of Marisol Touraine, France's Minister of Social Affairs and Health, Genevi-ve Fioraso, France's Minister of Higher Education and Research, and Professor Andr- Syrota, Chairman and CEO of Inserm.

5 Dec 2012

Arthrobotrys oligospora produces nanoparticles that could kill tumors

Arthrobotrys oligospora doesn't live a charmed life; it survives on a diet of roundworm. But a discovery by a team led by Mingjun Zhang, an associate professor of biomedical engineering at the University of Tennessee, Knoxville, could give the fungus's life more purpose-as a cancer fighter.

5 Dec 2012

Flexion raises $20M in Series B financing round

Flexion Therapeutics, Inc. today announced that the company has secured $20 million in a Series B financing round led by new investor, Novo Ventures.

4 Dec 2012

Diabetes tests: an interview with Dr. Danielle Stowasser

Diabetes is a serious condition that causes high levels of glucose (a type of sugar) in the blood. There are three main types of diabetes: type 1 and type 2 diabetes, which are lifelong conditions, and gestational diabetes, which only occurs in women during pregnancy.

3 Dec 2012

Chiropractic therapy gives parents something to smile about

Chiropractic manual therapy reduces crying behavior in infants with colic, study findings show.

3 Dec 2012

Pivotal Therapeutics reports loss of $811,164 for third quarter 2012

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on cardiovascular disease and overall health today announced its financial results and operational highlights for the quarter ended September 30, 2012. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.

30 Nov 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

ArmaGen closes $17M Series A financing

ArmaGen Technologies, Inc. today announced the closing of a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics.

29 Nov 2012

Disabling ItpkB enzyme improves function of Natural Killer cells

Researchers at The Scripps Research Institute (TRSI) are fueling the future of cancer treatment by improving a powerful tool in disease defense: the body's immune system. By revealing a novel but widespread cell signaling process, the scientists may have found a way to manipulate an important component of the immune system into more effectively fighting disease.

29 Nov 2012

Injecting Wnt7a protein could prevent Duchenne muscular dystrophy

Scientists have discovered that injecting a novel human protein into muscle affected by Duchenne muscular dystrophy significantly increases its size and strength, findings that could lead to a therapy akin to the use of insulin by diabetics.

28 Nov 2012

Study identifies gene signature associated with resistance to cancer therapies

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is associated with resistance to a broad range of cancer therapies in multiple cancer types.

28 Nov 2012